The medical information provided in this site is for educational purposes only and is the property of the American Osteopathic College of Dermatology. It is not intended nor implied to be a substitute for professional medical advice and shall not create a physician - patient relationship. If you have a specific question or concern about a skin lesion or disease, please consult a dermatologist. Any use, re-creation, dissemination, forwarding or copying of this information is strictly prohibited unless expressed written permission is given by the American Osteopathic College of Dermatology.
Total dose needles are available in the 5 most commonly used sizes - orange (16 and 25mm), blue (25mm and 30mm), and green (40mm).
Please note that Total Dose needles fit best on the Nevershare 2ml syringe, and do NOT fit on:
* Terumo 1ml, , or 5ml syringes;
* The BD 2ml 'Emerald' syringe;
* Frontier (and some other) 2ml, 5ml, and 10ml syringes; or
* Syringes with a spike that goes into the tip of the syringe.
Click on the images or product names below for more information.
The cortisol activity of MPA at these high doses is thought to increase serum glucose in rats which reactively stimulates the beta cells of the pancreatic islets to produce insulin. This repeated stimulation is thought to cause the tumours in rats. Similar lesions are not likely to occur in humans since the endocrine system of rats is more sensitive to hormones than that of women. When MPA is combined with estrogen, MPA binds to fewer glucocorticosteriod receptors and thus has less effect on plasma glucose. In humans, the diabetogenic response to MPA at therapeutic doses is slight. Moreover, an extensive literature search revealed no evidence that MPA causes pancreatic tumours in humans.